This defect is attributed to poor expression of DNAM-1 on NK cells and its ligand, CD155 on CD4+ T cells in the setting of MS (40), and is consistent with studies revealing that DNAM-1 polymorphisms may play a role in susceptibility to MS (42). The gene discussed is PVR; the disease is myeloid sarcoma.